Amedisys Reports Fourth Quarter and Year End 2018 Financial Results Issues 2019 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Amedisys (AMED) PT Lowered to $124 at Craig-Hallum
February 28, 2019 3:52 PM ESTCraig-Hallum analyst Kevin Ellich lowered the price target on Amedisys (NASDAQ: AMED) to $124.00 (from $132.00) while maintaining a Hold rating.
Ellich notes FY19 guidance was lower partially due to CCH integration.
... MoreAmedisys (AMED) Tops Q4 EPS by 6c, Offers FY Guidance
February 27, 2019 5:02 PM ESTAmedisys (NASDAQ: AMED) reported Q4 EPS of $0.91, $0.06 better than the analyst estimate of $0.85. Revenue for the quarter came in at $434.4 million versus the consensus estimate of $427.51 million.
GUIDANCE:
Amedisys sees FY2019 EPS of $3.98-$4.09, versus the consensus of $4.08. Amedisys sees... More
